Advanced search
Publication Cover
Platelets Volume 33, 2022 - Issue 6
Submit an article Journal homepage
296
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant

Hong Tian1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Danqing Kong1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Yun Li1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Chengyuan Gu1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Ziqiang Yu1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Zhaoyue Wang1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Depei Wu1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
&
Jie Yin1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2 Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3 Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 951-953 | Received 05 Oct 2021, Accepted 22 Nov 2021, Published online: 16 Dec 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Acquired amegakaryocytic thrombocypenia (AAMT) is an extremely rare hematologic disorder and standard treatment strategy has not been established. We described herein two cases of AAMT who were fully responded to eltrombopag and immunosuppressant. Patient 1 was refractory to steroid, IVIG and recombinant human thrombopoietin (rhTPO). Patient 2 did not respond to high dosage of steroid, IVIG, rhTPO and rituximab. Moreover, his AAMT progressed to aplastic anemia in 5 months. Both patients took eltrombopag and immunosuppressant, then they achieved long-term remission without obvious side effects. Our findings suggest that this combination can be a valuable alternative in AAMT.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by National Natural Science Foundation of China (No.81600105, No. 81900151), Natural Science Foundation of Jiangsu Province (BK20190176, BK20180202) and Open project of NHC Key Laboratory of Thrombosis and Hemostasis (KJS2137).

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later
PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.